A phase II study of ondansetron as antiemetic prophylaxis in patients receiving carboplatin for advanced ovarian cancer. The North Thames Ovary Group.
Thirty four patients who were receiving carboplatin 400 mg/m2 for advanced epithelial ovarian cancer were treated with ondansetron antiemetic prophylaxis. Ondansetron was given as 4 mg oral +4 mg iv 30 minutes prior to carboplatin followed by 8 mg oral tds for 5 days. Of the evaluable patients complete or major control of emesis on day one was achieved in 94% of previously untreated patients and 81% of patients refractory to conventional antiemetic therapy. For the 5 day period as a whole 88% of untreated patients and 69% of those with refractory emesis reported complete or major control of nausea and vomiting. Fifteen patients noted no side effects with mild headache (30%) and constipation (21%) the most frequent problems in the remainder. Ondansetron is effective antiemetic prophylaxis for carboplatin chemotherapy and should allow the majority of these patients to be managed on an out-patient basis.
Smith
D B
DB
Department of Medical Oncology, Charing Cross Hospital, London, U.K.
Rustin
G J
GJ
Howells
N
N
Lambert
H E
HE
McQuade
B
B
D000328:Adult; D000368:Aged; D016190:Carboplatin / Q000009:adverse effects* / Q000627:therapeutic use; D004848:Epithelium / Q000473:pathology; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000009:adverse effects / Q000627:therapeutic use*; D008875:Middle Aged; D009325:Nausea / Q000188:drug therapy*; D017294:Ondansetron; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D014839:Vomiting / Q000188:drug therapy*
D007093:Imidazoles; D017294:Ondansetron; D016190:Carboplatin